Matthew Wilson
Last active: 3/24/2020

Enhanced Expression of Anti-CD19 Chimeric Antigen Receptor in Transposon-Engineered T Cells.

Morita D, Nishio N, Saito S, Tanaka M, Kawashima N, Okuno Y, Suzuki S, Matsuda K, Maeda Y, Wilson MH, Dotti G, Rooney CM, Takahashi Y, Nakazawa Y
Mol Ther Methods Clin Dev. 2018 8: 131-140

PMID: 29687032 · PMCID: PMC5907825 · DOI:10.1016/j.omtm.2017.12.003

Adoptive T cell therapy using chimeric antigen receptor (CAR)-modified T cells is a promising cancer immunotherapy. We previously developed a non-viral method of gene transfer into T cells using a transposon system to improve the cost-effectiveness of CAR-T cell therapy. Here, we have further improved our technology by a novel culture strategy to increase the transfection efficiency and to reduce the time of T cell manufacturing. Using a CH2CH3-free CD19-specific CAR transposon vector and combining irradiated activated T cells (ATCs) as feeder cells and virus-specific T cell receptor (TCR) stimulation, we achieved 51.4% ± 14% CAR T cells and 2.8-fold expansion after 14 culture days. Expanded CD19.CAR-T cells maintained a significant fraction of CD45RACCR7 T cells and demonstrated potent antitumor activity against CD19 leukemic cells both and . Therefore, -based gene transfer may provide an alternative to viral gene transfer for CAR-T cell therapy.

MeSH Terms (0)

Connections (1)

This publication is referenced by other Labnodes entities: